Wednesday, July 30, 2025 7/30/2025

Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy

Award Number: R33CA267258
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/02/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy - Abstract The goal of cancer immunotherapy is to build long-lasting tumor-specific immunologic ‘memory’ in patients that enables the lifelong rejection of tumors. The two prominent types of antigen-specific cancer immunotherapy, adoptive T cell therapy and APC-based vaccination, both require expansion of anti-tumor T cells via APCs. However, for the purpose of effective adoptive T cell therapy, the critical question is how to generate, within a short period of time, large numbers of antitumor T cells. Furthermore, in vitro-expanded T cells must also possess the capacity to engraft, proliferate, and persist in vivo with sufficient antitumor function to induce sustained antitumor activity. Autologous antigen-presenting cells (APCs) such as DCs also have several serious limitations. The necessity to access large amounts of cancer patients’ blood to prepare autologous APC from each patient in a timely manner is cumbersome. To overcome these problems, we developed the microfluidic process to generate cell-sized unilamellar vesicles (CUVs) and decorated them with antigen presenting ligands for artificial APCs (or aAPCs). Preliminary results show that aAPCs are able to bind and interact with T cells and cause their expansion. The objective of the present proposal is to further optimize the aAPCs preparation and test its capacity to induce tumor specific responses in vitro and in vivo. The hypothesis is that the optimized aAPC functionalization will result in enhanced expansion of cytotoxic CD8 T cells and a reduction in tumor progression over the present one (original). The Specific Aims are- 1) Bioinspired optimization of artificial antigen presenting cell (aAPC) production via microfluidic engineering. We will insert the antigen presenting ligands in the membrane to mimic cells. The aAPCs will also be produced with hydrogel cytoskeletons to optimize its mechanical properties for maximum T cell expansion. 2) Evaluation of the capacity of aAPCs to induce tumor specific T cell responses in vitro. Using PBMCs from healthy donors and breast cancer patients we will evaluate the capacity of aAPCs to induce cytotoxic T cells. 3) Evaluation of the capacity of aAPCs to induce T cell responses and tumor killing with an in vivo mice tumor model. Methods to scale up the production of aAPCs for in vivo use will be developed. The capacity of aAPCs to kill tumor in vivo in mice will also be determined using a melanoma model. The goal is to produce an aAPC preparation that mimics cells, is stable, easy to produce in large quantities and capable of expanding tumor specific CD8 T cells for immunotherapy of cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $156,730 )
2025	2025	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Cancer Detection and Diagnosis Research	000	4	7/8/2025	NON-COMPETING CONTINUATION	$156,730
														Subtotal = $156,730

Issue Date FY: 2024 ( Subtotal = $205,000 )
2024	2024	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Cancer Detection and Diagnosis Research	000	3	9/10/2024	NON-COMPETING CONTINUATION	$205,000
														Subtotal = $205,000

Issue Date FY: 2023 ( Subtotal = $373,718 )
2023	2023	UNIVERSITY OF CALIFORNIA, IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Cancer Detection and Diagnosis Research	000	2	7/24/2023	NON-COMPETING CONTINUATION	$373,718
														Subtotal = $373,718

Issue Date FY: 2022 ( Subtotal = $367,506 )
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Detection and Diagnosis Research	000	1	9/2/2022	NEW	$367,506
														Subtotal = $367,506

Grand Total All Awards = $1,102,954

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy

Award Number: R33CA267258

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/02/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer